Kailera Therapeutics (NASDAQ:KLRA) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Kailera Therapeutics (NASDAQ:KLRA) to a hold rating in a research report released on Wednesday morning,Zacks.com reports.

Several other equities research analysts have also issued reports on KLRA. Jefferies Financial Group started coverage on shares of Kailera Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $48.00 price objective for the company. Leerink Partners initiated coverage on shares of Kailera Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 price target for the company. TD Cowen initiated coverage on shares of Kailera Therapeutics in a report on Tuesday. They set a “buy” rating and a $57.00 price target for the company. William Blair initiated coverage on shares of Kailera Therapeutics in a report on Tuesday. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of Kailera Therapeutics in a report on Tuesday. They set an “overweight” rating and a $30.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $42.75.

Kailera Therapeutics Stock Performance

Kailera Therapeutics stock opened at $21.50 on Wednesday. Kailera Therapeutics has a 52-week low of $20.86 and a 52-week high of $28.23.

Insider Activity at Kailera Therapeutics

In related news, Director Adam Koppel acquired 1,562,500 shares of Kailera Therapeutics stock in a transaction on Monday, April 20th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $25,000,000.00. Following the purchase, the director directly owned 22,583,268 shares of the company’s stock, valued at $361,332,288. The trade was a 7.43% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Rtw Investments, Lp acquired 500,000 shares of Kailera Therapeutics stock in a transaction on Monday, April 20th. The shares were bought at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the completion of the purchase, the insider directly owned 10,776,820 shares in the company, valued at $172,429,120. The trade was a 4.87% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 10,460,938 shares of company stock valued at $167,375,008.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.